- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07795866
An Exploratory Study to Evaluate Skin Brightening Effects of Different Cosmetic Formulations on UV Irradiated Tanning Model
26 augusti 2026 uppdaterad av: Unilever R&D
This is a double-blind randomized, complete block design study on Chinese population, expecting approximately 18 participants recruited and at least 10 participants to complete the whole 9-week study.
The study test sites will receive a single 2MED UV radiation .
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Studietyp
Interventionell
Inskrivning (Beräknad)
13
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Sunny Du
- Telefonnummer: +86 21 22128000
- E-post: Sunny.Du@unilever.com
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Healthy Chinese female or male, aged from 18 to 50 years old (both inclusive).
- Participants in good health condition as per the health history questionnaire with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data.
- Participant is able to read, understand and sign an appropriate informed consent form indicating his willingness to participate.
- ITA° range 10-42°; Skin type III and IV included and can tolerance 2MED radiation.
- No history of allergic diseases or allergies to cosmetics, UV light and other topical preparations.
- No history of photosensitive diseases and no recent use of medications that affect photosensitivity.
- The test area skin (back) should be free of birthmarks, inflammation, scars, excessive hair, etc.
- No cuts, abrasions, fissures, wounds, lacerations on the test site (back).
- Participants must understand the trial process, voluntarily participate in the study, and sign a written informed consent form.
- Willing to attend the study center twice daily for product application during the study period and complete all visits.
Exclusion Criteria:
- Study participants are employees of Sponsor or CRO.
- The study participants participated in test involving the test site within 2 months prior to the start of this test or are currently participating in such tests.
- Study participants had any other visible signs of local irritation, erythema, or skin disease on the visible parts of the body.
- Study participants consider they are prone to breakouts and/or sensitive skin.
- Study participants had a chronic illness or had major surgery in the past year.
- Study participants were receiving any skin treatments on the test sites.
- Study participants had allergies or sensitivities to cleansing products, creams/emulsion, costume jewelry, or other things.
- Female study participants were pregnant/breastfeeding or planning to become pregnant during the trial (study participants self-declared at screening visits).
- Study participants took medication for any condition, which the researchers believe may have affected the interpretation of the data.
- Study participants had a history of psoriasis, eczema, atopic dermatitis, severe acne, etc. Or have other chronic systemic diseases.
- Study participants had received oral or topical corticosteroids and other anti-inflammatory drugs within the last 1 month.
- Study participants used tartaric acid, salicylic acid and any other products or drugs that affect skin colour (such as hydroquinones) within the last 2 months.
- Study participants used retinoic acid preparations or aesthetic treatment such as chemical stripping, laser, pulsed light, etc. in the test site in the past three months.
- Study participants were inevitably exposed to prolonged sunlight.
- Clinical evaluation considers that participants are not suitable for the test.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Obehandlad
|
|
|
Placebo-jämförare: SMR 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: SMR 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: SMR 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: SMR 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: SMR 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Placebo-jämförare: Pro-Derma 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: Pro-Derma 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: Pro-Derma 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: Pro-Derma 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimentell: Pro-Derma 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Aktiv komparator: Thiamidol
|
Cosmetic skin brightening product to be applied to defined test site
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
L*, a*, b*, ITA
Tidsram: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin color (L*, a*, b* values, calculate ITA°) on the back test areas using Spectrophotometer, CM-26d.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Hydration and barrier function
Tidsram: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin hydration on the back test areas using Corneometer, CM825.
Measure TEWL on the back test areas using Vapometer .
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Image demo
Tidsram: From 1-week pre-treatment phase to end of study at 8 weeks
|
Capture images on the back test areas using Antera 3D device.
Capture images on the back test areas using digital camera.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
10 september 2026
Primärt slutförande (Beräknad)
11 november 2026
Avslutad studie (Beräknad)
11 november 2026
Studieregistreringsdatum
Först inskickad
26 augusti 2026
Först inskickad som uppfyllde QC-kriterierna
26 augusti 2026
Första postat (Faktisk)
31 augusti 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
31 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
26 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .